Alligator Bioscience AB: Interim report January–March 2021
High activity during the first quarter ”So far, 2021 has been characterized by high activity, with a research collaboration that validates o ...
Alligator Bioscience publishes Annual Report for 2020
Lund, Sweden, March 18, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2020 has been publi ...
Alligator Bioscience AB: Year-end Report January-December 2020
Continued focus on clinical development. “Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with meta ...
Alligator Bioscience AB (publ): Interim report January-September 2020
Encouraging clinical safety data for ATOR-1017 The Phase I study with ATOR-1017 has progressed exceptionally well and in August we presented ...
Alligator Bioscience AB (publ) Interim report January-June 2020
Promising safety data for ATOR-1015 "With the new strategy announced in early April, we have put a stronger focus on Alligator’s clinica ...
Alligator Bioscience AB (publ) Interim report January-March 2020
Stronger focus on clinical projects "The focusing of our operations protects the company’s liquidity, but is also part of our long-term ...
Alligator Bioscience’s Annual Report 2019 published
Lund, Sweden, 2 March 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutica ...
Alligator Bioscience AB Year-end Report January-December 2019
"2019 was the year when Alligator entered the clinical phase on a broad front. At the beginning of the year, we had one clinical project ...
Alligator Bioscience AB Interim report January-September 2019
"We are now regaining the exclusive, global rights to develop and commercialize ADC-1013 and at the same time receive enough ADC-1013 su ...